Suppr超能文献

[心肌梗死患者的溶栓剂类型与急性肾损伤发生率]

[Type of Thrombolytic Agent and Rate of Acute Kidney Injury in Patients With Myocardial Infarction].

作者信息

Menzorov M V, Shutov A M, Serov V A, Saenko Iu V, Grishen'kin L Iu

出版信息

Kardiologiia. 2015;55(2):16-20.

Abstract

Aim of this study was to assess incidence and severity of acute kidney injury (AKI) in patients with ST-elevation (STE) myocardial infarction (MI) after thrombolytic therapy with alteplase or streptokinase. Among 292 included patients (227 men, 65 women, mean age 58 ± 11 years) 170 received streptokinase, 122 - alteplase. Coronary angiography in acute stage of MI was an exclusion criterion. Thrombolysis was effective in 213 (73%) patients. There was no statistically significant difference in effectiveness of thrombolysis among streptokinase or alteplase treated patients. Incidence of AKI in patients with STEMI was 25%. Both incidence and severity of AKI were higher in streptokinase treated patients. Only stage II-III AKI was significantly associated with higher in-hospital mortality.

摘要

本研究的目的是评估使用阿替普酶或链激酶进行溶栓治疗的ST段抬高型(STE)心肌梗死(MI)患者急性肾损伤(AKI)的发生率和严重程度。在纳入的292例患者(227例男性,65例女性,平均年龄58±11岁)中,170例接受链激酶治疗,122例接受阿替普酶治疗。MI急性期的冠状动脉造影是排除标准。溶栓治疗对213例(73%)患者有效。链激酶或阿替普酶治疗患者之间的溶栓效果无统计学显著差异。STEMI患者中AKI的发生率为25%。链激酶治疗患者的AKI发生率和严重程度均较高。只有II-III期AKI与较高的住院死亡率显著相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验